Skip to main content

Pharmaceutical Process Chemistry for Synthesis: Rethinking the Routes to Scale-Up



Pharmaceutical Process Chemistry for Synthesis: Rethinking the Routes to Scale-Up

Peter J. Harrington

ISBN: 978-0-470-57755-4 February 2011 376 Pages


There is a need to explain that generic versions of a drug may not be manufactured by the same process as brand-name drugs and that the different processes may have dramatically different environmental impacts. Two global forces are at odds today—the push for "greener" processes and the push for lower drug prices. This book brings this conflict into sharp focus by discussing in detail the published process chemistry for top-selling small molecule drugs.

Providing insights about process route selection, choice of reagents, and reaction conditions, Pharmaceutical Process Chemistry for Synthesis guides process chemists in identifying best processes for manufacturing these blockbuster drugs as they lose patent protection. Further, it highlights the strategies and methodology that might be useful for expediting the process research and development of the blockbusters of the future.

Written from a refreshingly objective perspective, this book is essential for process chemists who need to devise practical syntheses for increasingly complex drugs in a constantly decreasing time frame.

1 Introduction.

2 Actos® (Pioglitazone Hydrochloride).

3 Lexapro® (Escitalopram Oxalate).

4 Efferox XR® (Venlafaxine Hydrochloride).

5 Seroquel® (Quetiapine Hemifumarate).

6 Singulair® (Montelukast Sodium).

7 Prevacid® (Lansoprazole).

8 Advair Diskus® (Salmeterol Xinafoate).

9 Lipitor® (Aatorvastatin Calcium).


"This book presents detailed discussions of the published process chemistry of the ten top-selling small molecule drugs in the US in 2007, information which is usually carefully protected by the current and future manufacturers." (, 17 March 2011)